Entrada Therapeutics, Inc. (TRDA) Financials
TRDA Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 485.0 million | 238.4 million |
2023-06-30 | 494.0 million | 287.1 million |
2023-03-31 | 475.6 million | 246.0 million |
2022-12-31 | 252.1 million | 39.5 million |
TRDA Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -25.9 million | 3.4 million |
2023-06-30 | -36.6 million | 3.1 million |
2023-03-31 | 201.7 million | 2.8 million |
2022-12-31 | -28.0 million | 2.9 million |
TRDA Net Income
No data available :(
TRDA Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 353.6 million | - | 69.1 million |
2023-06-30 | 376.8 million | - | 73.0 million |
2023-03-31 | 227.6 million | - | 16.2 million |
2022-12-31 | 45.2 million | - | 25.9 million |
TRDA Shares Outstanding
TRDA Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 1.4 million | 22.2 million | 7.5 million | - |
2023-06-30 | 1.5 million | 26.3 million | 8.2 million | - |
2023-03-31 | 1.7 million | 23.1 million | 7.9 million | - |
2022-12-31 | 708000 | 15.7 million | 9.9 million | - |
TRDA Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 43.7 million | 800000 |
2023-06-30 | 18.2 million | 700000 |
2023-03-31 | 25.3 million | 541000 |
2022-12-31 | - | 525000 |
TRDA
Price: $13.50
52 week price:
Earnings Per Share: -0.20 USD
P/E Ratio: -21.03
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 22900
Market Capitalization: 445.6 million